Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Seres Therapeutics Inc | MCRB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.7427 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.7427 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.54 - 6.65 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.7427 | USD |
Seres Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 111.75M | 151.01M | - | 126.33M | -113.72M | -0.75 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Seres Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MCRB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.58 | 0.829 | 0.54 | 0.7064414 | 5,810,375 | 0.1627 | 28.05% |
| 1 Month | 0.78 | 0.829 | 0.54 | 0.6954072 | 4,628,095 | -0.0373 | -4.78% |
| 3 Months | 1.13 | 1.24 | 0.54 | 0.8706753 | 4,141,342 | -0.3873 | -34.27% |
| 6 Months | 1.39 | 2.05 | 0.54 | 1.07 | 4,676,598 | -0.6473 | -46.57% |
| 1 Year | 6.22 | 6.65 | 0.54 | 2.25 | 3,775,433 | -5.48 | -88.06% |
| 3 Years | 20.65 | 25.055 | 0.54 | 4.47 | 2,094,807 | -19.91 | -96.40% |
| 5 Years | 7.01 | 38.50 | 0.54 | 7.43 | 1,590,342 | -6.27 | -89.41% |
Seres Therapeutics Description
| Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. |
